Nooc cusub oo mustaqbalka ah Daawooyinka Isku-jira ee Sclerosis
Haddii aad ku xanuunsato MS ama leedahay qof aad jeceshahay, taasi waxa laga yaabaa in aad waqti badan ku qaadato inaad ku fikirto, doonayso, ama aad u tukatid daaweyn ka wanaagsan, xitaa daaweyn. Warka wanaagsani waa in ay jiraan tiro badan oo ah MS therapy-ka lagu baranayo hadda, labadaba shaybaarka iyo tijaabooyinka gudaha caafimaad. Hal ilbiriqsi oo lagu hormarinayo ayaa ah horumarinta tallaalka MS.
Kala saarista tallaalka MS Tallaalka kale
Marka aad ka fekereyso tallaalada, inteenna intooda badani waxay ka fekerayaan in la geliyo gacmaheena si loo helo cirbado naga horjoogsanaya in aan helno tiro cudurro halis ah, sida hargabka, jadeecada, ama jadeecada. Tallaaladani waxaa ku jira fayruus ama bakteeriya la daciifiyay ama la dilay si aysan iyaga u dhicin inay runtii xanuunsan yihiin, laakiin waxaan ku qaldameeynaa nidaamkayaga difaaca si loo falanqeeyo jawaabta.
Hase yeeshee yoolka talaalka MS maaha mid ka hortag ah. Taas bedelkeed, waa hab-daaweyn. Tani macnaheedu waa in la siin doono si looga hortago ama loo yareeyo darnaanta calaamadaha MS-da la xidhiidha iyo dhibaatooyinka caafimaad ee qofka horay looga helay cudurka MS.
Farqiga kale ee u dhexeeya tallaalka dabiiciga ah iyo astaamaha tallaalka MS waa tallaal dhaqameedka loogu talagalay inay ka hortagaan cudurrada faafa - taas oo ah, cudur ah natiijada ka dhalan karta jeermisyada shisheeye sida fayrasyada ama bakteeriyada.
Si kastaba ha ahaatee, MS maahan cudur infekshin leh. Taa baddalkeeda, MS waa cudur ba'an. Sababaha qaar, nidaamyadeena difaaca jirka ayaa weerara maskaxda iyo maskaxda dareenka ee nidaamkayaga dhexe ee dareenka . Si kale haddii loo dhigo, MS waxaa sababa waxyaabo jidhkeenu ay samaynayaan laftiisa, oo aan sabab u ahayn dagaalyahan ajnabi ah.
Sidaa darteed, qaybaha ka midka ah musharraxiinta tallaalka MS ma ahan jeermisyo laakiin waxyaabo kale oo loogu talagalay in lagu 'rogo' nidaamyada difaaca hababka kala duwan ee looga joojiyo unugyada difaaca jirka inay weeraraan maskaxda iyo xudunta lafdhabarta.
Maxay Tijaabooyinka MS ee Diidan yihiin?
Halkan waxaa ku yaal afar tijaabo oo kala duwan oo ah tijaabada MS tallaal: Tcelna, NeuroVax, BHT-3009, iyo RTL1000. Mid kasta oo ka mid ah tallaaladani waxay isticmaalaan hab kala duwan si ay u gaaraan himiladooda joojinta dhaqdhaqaaqa gawaarida ee ka hortagga maskaxda.
Tcelna (horay Tovaxin): Tcelna-oo loo yaqaanno Tovaxin-waa tallaalka autologous T-cell, taasoo macnaheedu yahay in uu ka kooban yahay unugyada unugyada reebi-ga ee myelin-reactive, kuwa mas'uulka ka ah weerarka maskaxda ee dadka qaba MS, kuwaas oo la dilay. Marka la isku duro qiyaas aad u weyn oo ku soo noqda qofka, Tovaxin wuxuu helayaa nidaamka difaaca si uu u baabi'iyo inta kale ee unugyada wareegga iyada oo aan saameyn ku yeelan habka difaaca jirka.
Tallaalkan ayaa lagu arkay in uu yahay mid nabdoon, hase yeeshee si weyn ugama yareyn tirada guud ee cudurrada MS-da ee kordhinta MS ee baaritaanka ah 150 bukaan ah 2008-dii. Hadda waxa la socda tijaabo caafimaad oo cusub, oo la bilaabay 2012-ka magaca Tcelna, si loo qiimeeyo doorka yareynta dhimirka maskaxda iyo dib u dhigida naafada.
NeuroVax: NeuroVax waa talaal peptide-ka ah taleefoonka T-cell, taas oo macnaheedu yahay in laga sameeyo qaybo borotiinka ah oo u eg qaybo ka mid ah unugyada T infotta ee weerarta myelin. Waxaa loogu talagalay in lagu dhiirigeliyo jirka in uu sameeyo wax badan oo ka mid ah unugyada qawaaniinta T-da ee xakameynaya waxqabadka cudurkan pathogenic, ama "xun" T-cells.
Neurovax waxaa lagu mudayaa muruqa 4-dii todobaad kasta. Wajiga 2aad ee tijaabada caafimaadka ee loogu talagalay horumarinta labaad ee hormoonada ah ee sclerosis ayaa hadda loo sameeyay tallaalkan tijaabada ah.
BHT-3009: Tallaalkani waxa uu ka samaysan yahay DNA DNA ah oo la jaangooyo oo u eg unugyada maskaxda ee maskaxda in unugyada unugyada difaaca jirka ee loo yaqaan 'myelin basic'.
Ujeeddadiisu waxay tahay in la qeexo "isbeddel" kaas oo xakamaynaya jawaab celinta difaaca jirka, iyadoo la adeegsanayo "reeducating" unugyada difaaca ee weerara fayrasta miinada ee dadka qaba MS.
Daraasado cilmi baaris ah ayaa muujinaya in tallaalka uu yahay mid amaan ah oo si fiican u dulqaadan kara waxaana laga yaabaa inuu dhowaan galo tijaabooyinka Xaaladda Phase III.
RTL1000: "RTL" waa u gaaban yahay "dibudhisidda daawada T-cell Reciptor," kuwaas oo ah borotiinno ku xiran bararka T-unda ee dhaawici kara myelin dadka qaba MS. Iyadoo la xirayo kuwa soo dhaweynta, T-yada unugyada awood uma leh in ay sameeyaan waxyeello. Khubarada qaarkood ma ku darayaan middan qaybta "tallaalka" inta ay kuwa kale sameeyaan.
RTL1000 waxaa lagu ogaadey inay tahay mid amaan ah oo loo dulqaadan karo iyada oo ah hal maamul oo keliya oo lagu xidho tijaabo yar yar oo ah qaybta 1aad ee kiliiniga. Cilmi baadhayaashu waxay qorsheynayaan inay hore u socdaan si ay u tijaabiyaan amnigooda iyo waxtarkooda ayadoo la marayo ficilo badan oo bil walba ah oo ku jira marxaladda 2aad.
Horumarinta xiisaha ee kudhisan Multiple Sclerosis
Tallaalladani waxay ina siinayaan rajo badan. Haa, waxay weli ku jiraan imtixaan iyo fogaan badan oo diyaar u ah inta badan annaga. Si kastaba ha noqotee, waa kuwo aad u xiiso leh. Tixgeli iyaga oo dhakhtarkaaga kala hadla oo raacaya tijaabooyinka Diiwaanka Daawooyinka Daaweynta .
Ilaha:
Correale J, Fare M, Gilmore W. Tallaalada loogu talagalay cudurka sclerosis: horukac. CNS Daroogooyinka. 2008; 22 (3): 175-98.
Correale J & Fiol M. BHT-3009, oo ah maaddada 'myinemia basic protein-encoding plasmid' loogu talagalay daaweynta cudurka sclerosis. Curr Opin Mol Ther . 2009 Aug 11 (4): 463-70.
Ururka 'Multiple Sclerosis Association of America'. (2013). Daawooyinka Daawada: Tcelna (Tovaxin hore). Dib loo soo celiyay Janaayo 10-keedii 2015.
Ururka 'Multiple Sclerosis Association of America'. (2013). Daawooyinka Daawada: BHT-3009. Laga soo bilaabo Jannaayo 19th 2015.
Yadav V et al. Recombinant T-Cell Receptor Ligand (RTL) ee loogu talagalay daaweynta cudurka Multiple Sclerosis: Labo-indho la ', xakameyn-xakameyn, waji 1, daraasad-kordhin daraasad. Autoimmune Dis . 2012; 2012: 954739.